Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06987383 · ClinicalTrials.gov registry record · Phase 3
Vibegron for ENergy Thinking and Resilience in Aging
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT06987383 is a Phase 3 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants.
The verdict
NCT06987383, a Phase 3 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Interventions
- DRUG Placebo
- DRUG Vibegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06987383
The ClinicalTrials.gov registry entry for NCT06987383 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06987383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06987383 about?
NCT06987383 is a clinical study titled "Vibegron for ENergy Thinking and Resilience in Aging". This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
What is the current status of trial NCT06987383?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2026-08. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06987383?
The interventions under investigation include: Placebo (DRUG), Vibegron (DRUG).
Who is sponsoring clinical trial NCT06987383?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.